메뉴 건너뛰기




Volumn 13, Issue 22, 2007, Pages 6703-6711

Population pharmacokinetic analysis of topotecan in pediatric cancer patients

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DEXAMETHASONE; PHENYTOIN; TOPOTECAN;

EID: 36749019139     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1376     Document Type: Article
Times cited : (19)

References (28)
  • 1
    • 0026487210 scopus 로고
    • Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors
    • Houghton PJ, Chesire PJ, Myers L, Stewart CF, Synold TW, Houghton JA. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 1992;31:229-39.
    • (1992) Cancer Chemother Pharmacol , vol.31 , pp. 229-239
    • Houghton, P.J.1    Chesire, P.J.2    Myers, L.3    Stewart, C.F.4    Synold, T.W.5    Houghton, J.A.6
  • 2
    • 0029116438 scopus 로고
    • Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors
    • Houghton PJ, Cheshire PJ, Hallman JD, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995;36:393-403.
    • (1995) Cancer Chemother Pharmacol , vol.36 , pp. 393-403
    • Houghton, P.J.1    Cheshire, P.J.2    Hallman, J.D.3
  • 3
    • 0037087762 scopus 로고    scopus 로고
    • Protracted intermittent schedule of topotecan in children with refractory acute leukemia: A Pediatric Oncology Group study
    • Furman WL, Stewart CF, Kirstein M, et al. Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a Pediatric Oncology Group study. J Clin Oncol 2002;20:1617-24.
    • (2002) J Clin Oncol , vol.20 , pp. 1617-1624
    • Furman, W.L.1    Stewart, C.F.2    Kirstein, M.3
  • 4
    • 0028357993 scopus 로고
    • Phase I study of topotecan for pediatric patients with malignant solid tumors
    • Pratt CB, Stewart CF, Santana VM, et al. Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 1994;12:539-43.
    • (1994) J Clin Oncol , vol.12 , pp. 539-543
    • Pratt, C.B.1    Stewart, C.F.2    Santana, V.M.3
  • 5
    • 0037316914 scopus 로고    scopus 로고
    • A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors
    • Santana VM, Zamboni WC, Kirstein MN, et al. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res 2003;9:633-40.
    • (2003) Clin Cancer Res , vol.9 , pp. 633-640
    • Santana, V.M.1    Zamboni, W.C.2    Kirstein, M.N.3
  • 6
    • 4344566362 scopus 로고    scopus 로고
    • Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor
    • Stewart CF, Iacono LC, Chintagumpala M, et al. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol 2004;22:3357-65.
    • (2004) J Clin Oncol , vol.22 , pp. 3357-3365
    • Stewart, C.F.1    Iacono, L.C.2    Chintagumpala, M.3
  • 7
    • 0036140067 scopus 로고    scopus 로고
    • Phase I study of combination topotecan and carboplatin in pediatric solid tumors
    • Athale UH, Stewart C, Kuttesch JF, et al. Phase I study of combination topotecan and carboplatin in pediatric solid tumors. J Clin Oncol 2002;20:88-95.
    • (2002) J Clin Oncol , vol.20 , pp. 88-95
    • Athale, U.H.1    Stewart, C.2    Kuttesch, J.F.3
  • 8
    • 0035424844 scopus 로고    scopus 로고
    • Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group phase II study
    • Saylors RL, III, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001;19:3463-9.
    • (2001) J Clin Oncol , vol.19 , pp. 3463-3469
    • Saylors III, R.L.1    Stine, K.C.2    Sullivan, J.3
  • 9
    • 0028130504 scopus 로고
    • Clinical pharmacodynamics of continuous infusion topotecan in children: Systemic exposure predicts hematologic toxicity
    • Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR, Pratt CB. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J Clin Oncol 1994;12:1946-54.
    • (1994) J Clin Oncol , vol.12 , pp. 1946-1954
    • Stewart, C.F.1    Baker, S.D.2    Heideman, R.L.3    Jones, D.4    Crom, W.R.5    Pratt, C.B.6
  • 10
    • 0032054147 scopus 로고    scopus 로고
    • Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts
    • Zamboni WC, Stewart CF, Thompson J, et al. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst 1998;90:505-11.
    • (1998) J Natl Cancer Inst , vol.90 , pp. 505-511
    • Zamboni, W.C.1    Stewart, C.F.2    Thompson, J.3
  • 11
    • 10244270659 scopus 로고    scopus 로고
    • Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: A pediatric oncology group study
    • Tubergen DG, Stewart CF, Pratt CB, et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol 1996;18:352-61.
    • (1996) J Pediatr Hematol Oncol , vol.18 , pp. 352-361
    • Tubergen, D.G.1    Stewart, C.F.2    Pratt, C.B.3
  • 12
    • 23044452535 scopus 로고    scopus 로고
    • Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach
    • Santana VM, Furman WL, Billups CA, et al. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol 2005;23:4039-47.
    • (2005) J Clin Oncol , vol.23 , pp. 4039-4047
    • Santana, V.M.1    Furman, W.L.2    Billups, C.A.3
  • 13
    • 0032920492 scopus 로고    scopus 로고
    • Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors
    • Zamboni WC, Bowman LC, Tan M, et al. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemother Pharmacol 1999;43:454-60.
    • (1999) Cancer Chemother Pharmacol , vol.43 , pp. 454-460
    • Zamboni, W.C.1    Bowman, L.C.2    Tan, M.3
  • 14
    • 36749093099 scopus 로고    scopus 로고
    • NONMEM Users' Guide Part I-VIII. San Francisco (CA): NONMEM Project Group, University of California at San Francisco; 1998.
    • NONMEM Users' Guide Part I-VIII. San Francisco (CA): NONMEM Project Group, University of California at San Francisco; 1998.
  • 15
    • 23744450342 scopus 로고    scopus 로고
    • Monte Carlo parametric expectation maximization (MC-PEM) method for analyzing population pharmacokinetic/pharmacodynamic data
    • D'Argenio DZ, editor, NewYork NY, Springer;
    • Bauer RJ, Guzy S. Monte Carlo parametric expectation maximization (MC-PEM) method for analyzing population pharmacokinetic/pharmacodynamic data. In: D'Argenio DZ, editor. Advanced methods of pharmacokinetics and pharmacodynamic systems analysis. NewYork (NY): Springer; 2004.
    • (2004) Advanced methods of pharmacokinetics and pharmacodynamic systems analysis
    • Bauer, R.J.1    Guzy, S.2
  • 16
    • 18344394148 scopus 로고    scopus 로고
    • Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors
    • Mould DR, Holford NH, Schellens JH, et al. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther 2002;71:334-48.
    • (2002) Clin Pharmacol Ther , vol.71 , pp. 334-348
    • Mould, D.R.1    Holford, N.H.2    Schellens, J.H.3
  • 17
    • 0037764013 scopus 로고    scopus 로고
    • Glomerular filtration rate in children with solid tumors: Normative values and a new method for estimation
    • Brandt JR, Wong C, Jones DR, et al. Glomerular filtration rate in children with solid tumors: normative values and a new method for estimation. Pediatr Hematol Oncol 2003;20:309-18.
    • (2003) Pediatr Hematol Oncol , vol.20 , pp. 309-318
    • Brandt, J.R.1    Wong, C.2    Jones, D.R.3
  • 18
    • 33750335084 scopus 로고    scopus 로고
    • Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients
    • Hennig S, Wainwright CE, Bell SC, Miller H, Friberg LE, Charles BG. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Clin Pharmacokinet 2006;45:1099-114.
    • (2006) Clin Pharmacokinet , vol.45 , pp. 1099-1114
    • Hennig, S.1    Wainwright, C.E.2    Bell, S.C.3    Miller, H.4    Friberg, L.E.5    Charles, B.G.6
  • 19
    • 81255204082 scopus 로고    scopus 로고
    • Nonlinear mixed effects models: Practical issues
    • Bonate PL, editor, New York NY, Springer Science-Business Media, Inc
    • Bonate P. Nonlinear mixed effects models: practical issues. In: Bonate PL, editor. Pharmacokinetic-pharmacodynamic modeling and simulation. New York (NY): Springer Science-Business Media, Inc.; 2006. p. 267-307.
    • (2006) Pharmacokinetic-pharmacodynamic modeling and simulation , pp. 267-307
    • Bonate, P.1
  • 20
    • 0019604592 scopus 로고
    • Some suggestions for measuring predictive performance
    • Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9:503-12.
    • (1981) J Pharmacokinet Biopharm , vol.9 , pp. 503-512
    • Sheiner, L.B.1    Beal, S.L.2
  • 21
    • 0031924558 scopus 로고    scopus 로고
    • Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma
    • Zamboni WC, Gajjar AJ, Heideman RL, et al. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res 1998;4:783-9.
    • (1998) Clin Cancer Res , vol.4 , pp. 783-789
    • Zamboni, W.C.1    Gajjar, A.J.2    Heideman, R.L.3
  • 22
    • 0034086522 scopus 로고    scopus 로고
    • Population pharmacokinetic model for topotecan derived from phase I clinical trials
    • Gallo JM, Laub PB, Rowinsky EK, Grochow LB, Baker SD. Population pharmacokinetic model for topotecan derived from phase I clinical trials. J Clin Oncol 2000;18:2459-67.
    • (2000) J Clin Oncol , vol.18 , pp. 2459-2467
    • Gallo, J.M.1    Laub, P.B.2    Rowinsky, E.K.3    Grochow, L.B.4    Baker, S.D.5
  • 23
    • 0033729430 scopus 로고    scopus 로고
    • Population pharmacokinetics of topotecan: Intraindividual variability in total drug
    • Montazeri A, Boucaud M, Lokiec F, et al. Population pharmacokinetics of topotecan: intraindividual variability in total drug. Cancer Chemother Pharmacol 2000;46:375-81.
    • (2000) Cancer Chemother Pharmacol , vol.46 , pp. 375-381
    • Montazeri, A.1    Boucaud, M.2    Lokiec, F.3
  • 24
    • 1342322765 scopus 로고    scopus 로고
    • Factors affecting pharmacokinetic variability of oral topotecan: A population analysis
    • Leger F, Loos WJ, Fourcade J, et al. Factors affecting pharmacokinetic variability of oral topotecan: a population analysis. Br J Cancer 2004;90:343-7.
    • (2004) Br J Cancer , vol.90 , pp. 343-347
    • Leger, F.1    Loos, W.J.2    Fourcade, J.3
  • 25
    • 0141889555 scopus 로고    scopus 로고
    • Modeling plasma and saliva topotecan concentration time course using a population approach
    • Boucaud M, Pinguet F, Culine S, et al. Modeling plasma and saliva topotecan concentration time course using a population approach. Oncol Res 2003;13:211-9.
    • (2003) Oncol Res , vol.13 , pp. 211-219
    • Boucaud, M.1    Pinguet, F.2    Culine, S.3
  • 26
    • 0029810681 scopus 로고    scopus 로고
    • Topoisomerase I interactive drugs in children with cancer
    • Stewart CF, Zamboni WC, Crom WR, et al. Topoisomerase I interactive drugs in children with cancer. Invest New Drugs 1996;14:37-47.
    • (1996) Invest New Drugs , vol.14 , pp. 37-47
    • Stewart, C.F.1    Zamboni, W.C.2    Crom, W.R.3
  • 28
    • 15444358162 scopus 로고    scopus 로고
    • Probenecid alters topotecan systemic and renal disposition by inhibiting tubular secretion
    • Zamboni WC, Houghton PJ, Johnson RK, et al. Probenecid alters topotecan systemic and renal disposition by inhibiting tubular secretion. J Pharmacol Exp Ther 1998;284:89-94.
    • (1998) J Pharmacol Exp Ther , vol.284 , pp. 89-94
    • Zamboni, W.C.1    Houghton, P.J.2    Johnson, R.K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.